In stunning about-face, FDA invites Eli Lilly to quickly refile blockbuster hopeful baricitinib
Just a few weeks ago Eli Lilly $LLY made it clear that the FDA was demanding a new clinical study to clarify the safety …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
